Table 2.
Parameters | Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Age ≥ 60 years | 0.993 | 0.783—1.260 | 0.957 | |||
Female | 0.957 | 0.752—1.217 | 0.719 | |||
BMI ≥ 24 kg/m2 | 0.891 | 0.706—1.124 | 0.328 | |||
ASA score 1–2 | 1.051 | 0.724—1.526 | 0.794 | |||
Primary site colon | 1.052 | 0.833—1.330 | 0.669 | |||
Right hemicolon | 1.066 | 0.781—1.453 | 0.688 | |||
R0 resectiona | 0.515 | 0.404—0.658 | < 0.001* | 0.583 | 0.453—0.748 | < 0.001* |
Poorly differentiateda | 1.286 | 0.990—1.671 | 0.060 | 0.684 | ||
T3-T4a | 1.490 | 0.935—2.374 | 0.093 | 0.262 | ||
N1-N2a | 1.749 | 1.332—2.295 | < 0.001* | 1.511 | 1.145—1.994 | 0.004* |
Synchronous metastasisa | 1.451 | 1.087—1.937 | 0.012* | 0.143 | ||
Extrahepatic metastasesa | 1.612 | 1.160—2.239 | 0.004* | 1.416 | 1.015—1.976 | 0.041* |
Diameter of metastases > 5 cm | 1.038 | 0.722—1.492 | 0.841 | |||
Multiple metastasesa | 1.997 | 1.571—2.539 | < 0.001* | 0.063 | ||
Bilobar distributiona | 2.035 | 1.603—2.583 | < 0.001* | 0.115 | ||
Preoperative CEA > 50 ng/mla | 1.569 | 1.183—2.082 | 0.002* | 1.400 | 1.053—1.861 | 0.021* |
Major liver resectiona | 1.978 | 1.563—2.503 | < 0.001* | 1.615 | 1.266—2.060 | < 0.001* |
Hepatectomy only | 0.869 | 0.678—1.113 | 0.267 | |||
Radio frequency ablationa | 1.818 | 1.289—2.565 | 0.001* | 0.153 | ||
Preoperative chemotherapya | 1.481 | 1.170—1.874 | 0.001* | 0.204 | ||
Postoperative chemotherapy | 0.870 | 0.689—1.098 | 0.241 | |||
Comorbidity | 0.960 | 0.760—1.213 | 0.731 | |||
Postoperative complicationa | 1.393 | 1.103—1.757 | 0.005* | 0.161 | ||
Postoperative major complication | 1.120 | 0.827—1.517 | 0.463 | |||
Serious operation injury conditiona | 1.616 | 1.279—2.042 | < 0.001* | 0.062 | ||
AMLRI > 3.33a | 1.530 | 1.114—2.101 | 0.009* | 1.462 | 1.059—2.019 | 0.021 * |
AST > 14 U/L | 1.697 | 1.133—2.542 | 0.010* | |||
MLR > 0.15 | 1.397 | 0.953—2.046 | 0.086 | |||
Blood loss (ml) | 1.521 | 1.157—1.999 | 0.003* | |||
Operation time (min) | 1.572 | 1.240—1.993 | < 0.001* | |||
CRS 3–5 | 1.608 | 1.272—2.032 | < 0.001* |
BMI body mass index, ASA American Society of Anesthesiologists T tumour staging, N lymph node staging, CEA carcinoembryonic antigen, CRS clinical risk score, AMLRI AST·MLR index, AST aspartate aminotransferase, MLR monocyte-to-lymphocyte ratio
aIncluded in multivariable analysis
*Statistically significant